Sarah Fromson

JPMorgan Global Emerging Markets Income Trust Plc operates as a mutual fund closed-end investment trust. Its investment objective is to provide investors with a dividend income combined with the potential for long-term capital growth from investing in a portfolio of emerging market investments. The firm also invests in equities, unlisted equities, debt securities, convertible securities and cash, and cash equivalents. The company was founded on June 4, 2010 and is headquartered in London, the United Kingdom.

The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK.

RBS Asset Management Ltd. (RBSAML) is the Great Britain-based investment advisory subsidiary of Royal Bank of Scotland Plc, itself a subsidiary of state-owned Royal Bank of Scotland Group Plc. (LSE, ADR: RBS) in Edinburgh, Scotland. Established in 2004, the firm is located in London and provides a range of traditional and alternative asset class investments including credit, private equity, funds of hedge funds and multi-manager strategies to institutional investors such as private banks, financial institutions, family offices, charities, asset management firms and government bodies.

Baronsmead Second Venture Trust plc operates as a traded fund,invest in companies located in the United Kingdom. The fund targets companies operating in fields of technology, healthcare and hospitality businesses sectors. It provides financing for early and growth stage capital requirements.

Part of The Wellcome Trust Ltd., Genome Research Ltd. is a world-leading genomics research institute founded in 1992. The company is based in Cambridge, UK. Genome Research delivers therapeutic, diagnostic, and production benefits in areas such as cancer, immunology, public health, and personalized treatment. The British company tackle some of the most difficult challenges in genomic research, demanding science at scale and a visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways. The company's work helps improve human health and understand life on a molecular level.